Medarex
Global biopharmaceutical company focused on discovery, development and delivery of medicines across oncology, hematology, neuroscience, immunology and cardiovascular disease. Operates integrated R&D, clinical development, supply chain and commercialization functions and applies data-driven and AI methods across discovery, development and patient support programs.
Industries
Nr. of Employees
Very Large (1000+)
Medarex
Princeton, New Jersey, United States, North America
Products
Pipeline portfolio (preclinical to registrational)
Diversified development portfolio spanning small molecules, biologics, cell therapies, targeted degraders and radiopharmaceuticals across multiple disease areas.
Protein degrader discovery platforms
Research platforms for design and development of degraders to target disease-relevant proteins not tractable with classical inhibition.
Marketed medicines portfolio and information resources
Catalog of marketed therapeutic products with maintained prescribing information, medication guides and patient support programs.
Pipeline portfolio (preclinical to registrational)
Diversified development portfolio spanning small molecules, biologics, cell therapies, targeted degraders and radiopharmaceuticals across multiple disease areas.
Protein degrader discovery platforms
Research platforms for design and development of degraders to target disease-relevant proteins not tractable with classical inhibition.
Marketed medicines portfolio and information resources
Catalog of marketed therapeutic products with maintained prescribing information, medication guides and patient support programs.
Services
Portal-based submission, governance review and potential material or grant support for investigator-initiated research.
Processes to disclose clinical trial information, accept data requests and publish plain-language summaries of study results for participants and researchers.
Global adverse event intake, safety surveillance and regulatory-compliant reporting channels, plus risk mitigation program management.
Global supply chain management for investigational medicines including IRT-managed randomization, inventory control and coordinated shipments to clinical sites.
Design and integration of patient-facing digital tools and wearable biosensor data capture to support remote monitoring and real-world evidence collection.
Services to assist with insurance coverage questions, prior authorization, co-pay assistance and patient assistance programs to improve treatment access.
Portal-based submission, governance review and potential material or grant support for investigator-initiated research.
Processes to disclose clinical trial information, accept data requests and publish plain-language summaries of study results for participants and researchers.
Global adverse event intake, safety surveillance and regulatory-compliant reporting channels, plus risk mitigation program management.
Global supply chain management for investigational medicines including IRT-managed randomization, inventory control and coordinated shipments to clinical sites.
Design and integration of patient-facing digital tools and wearable biosensor data capture to support remote monitoring and real-world evidence collection.
Services to assist with insurance coverage questions, prior authorization, co-pay assistance and patient assistance programs to improve treatment access.
Expertise Areas
- Clinical trial management and global operations
- Translational medicine and quantitative modeling
- Targeted protein degradation discovery
- Cell therapy development and GMP manufacturing
Key Technologies
- Targeted protein degradation platforms
- Cell therapy manufacturing and delivery
- Radiopharmaceutical delivery methods
- Antibody-drug/conjugate modalities
News & Updates
Regulatory accelerated approval granted for an oncology regimen as described in a company press release.
Article describing clinical trial orchestration, global supply chain operations, interactive response system usage and product development support for clinical programs.
Feature describing research into targeted protein degradation modalities and associated discovery approaches.
Reported 49 compounds in development across 40+ disease areas as of July 30, 2026.
Regulatory accelerated approval granted for an oncology regimen as described in a company press release.
Article describing clinical trial orchestration, global supply chain operations, interactive response system usage and product development support for clinical programs.
Feature describing research into targeted protein degradation modalities and associated discovery approaches.
Reported 49 compounds in development across 40+ disease areas as of July 30, 2026.